Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699582 | 1.00 | MMP1 (0.48) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL8114734 | 1.00 | MMP1 (0.48) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL24567516 | 0.84 | MMP1 (0.47) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL23613007 | 0.82 | ALDH1A1 (0.43) | SMN1; SMN2PKMKMT2AMEN1CNR2 | |
| SCHEMBL15894960 | 0.82 | MMP1 (0.45) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL15083020 | 0.82 | MMP1 (0.45) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL24160865 | 0.82 | MMP1 (0.45) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL24568605 | 0.82 | MMP1 (0.45) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL21666433 | 0.82 | MMP1 (0.45) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL13887653 | 0.81 | ASAH1 (0.38) | CNR2L3MBTL1ALDH1A1MAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230271957-A1 | CONDENSED PYRAZOLE DERIVATIVES AS INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20190125753-A1 | COMPOUNDS AND METHODS FOR INCREASING HEMATOPOIESIS | UNIV SOUTHERN CALIFORNIA (US) | 2019-05-02 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | MMP1 4198/4885MMP2 3788/4885MMP3 3512/4885 |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MMP1 3380/4885MMP2 3549/4885MMP3 4005/4885 |
| US-20230271957-A1 | CONDENSED PYRAZOLE DERIVATIVES AS INHIBITORS OF SARM1 | SARM1, SMN1; SMN2, AIFM1 | MMP1 2780/4885MMP2 1881/4885MMP3 2094/4885 |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | MMP1 1735/4885MMP2 527/4885MMP3 1356/4885 |
| US-20190125753-A1 | COMPOUNDS AND METHODS FOR INCREASING HEMATOPOIESIS | CTNNB1, CTNNA1, HCLS1 | MMP1 4040/4885MMP2 4134/4885MMP3 3084/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | MMP1 4276/4885MMP2 3883/4885MMP3 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.